AdvaMed Plays Tariff Chess, Trump Plays Checkers
As tariff uncertainty continues in 2025, AdvaMed plays tariff chess, advocating for predictable, zero-for-zero policies to protect medtech innovation and access.
Resource Library
Access our full library of guidance, white papers, and other resources developed by and for the medical technology industry.
Filter By:
AdvaMed® Advancements: Q4 2025 Report
AdvaMed® Advancements: Q4 2025 Report highlights how unified industry advocacy responded to policy disruption, trade uncertainty, and federal action impacting medtech.
From Category to Capabilities: Rethinking Procurement Through the Business Lens
Read how shifting to a capability-driven procurement model enables medtech organizations to better align sourcing decisions with business strategy, and strengthen cross-functional collaboration.
RFI: National Strategic Plan for Advanced Manufacturing Letter
This comment letter from AdvaMed responds to the OSTP’s Request for Information on National Strategic Plan for Advanced Manufacturing (“OSTP RFI”).
AdvaMed® Advancements: Q3 2025 Report
AdvaMed® Advancements: Q3 2025 Report. Amid an increasingly charged political environment, AdvaMed remained a steady, persuasive voice for medtech innovation. From mobilizing rapid action on the Section 232 investigation to…
Listen to AdvaMed®'s Podcast
Brought to you by AdvaMed®, Medtech POV with Scott Whitaker is a podcast that covers the intersection of medtech and policy from every perspective.
AdvaMed® Device and Diagnostics Compliance Group Benchmarking | Meals
AdvaMed® periodically compiles benchmarking data on Member companies’ policies regarding the provision of meals and refreshments to U.S. Health Care Professionals to assist companies in understanding industry trends and practices…
The Economic Impact of the Medical Technology Industry 2024
Explore AdvaMed’s 2024 Economic Impact Report, developed by Frost & Sullivan, highlighting medtech’s vital contributions to the U.S. economy
AdvaMed Comments on OSTP Request for Information: Regulatory Reform on Artificial Intelligence
AdvaMed® Advancements: Q3 2025 Report. Amid an increasingly charged political environment, AdvaMed remained a steady, persuasive voice for medtech innovation. From mobilizing rapid action on the Section 232 investigation to…
AdvaMed Code of Ethics®
Achieve the highest levels of compliance with principles on consulting arrangements, training, education and other forms of communications.